Celularity Inc. announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors. Dr. Ling, a distinguished academic and military physician-scientist with a strong background in regenerative medicine and a deep commitment to advancing healthcare, will bring invaluable expertise and insights to Celularity as it continues to pioneer innovative therapies for patients in need. Throughout his career, Dr. Ling has made significant contributions to regenerative medicine and stem cell therapy, earning him recognition as a thought leader in these areas.

He has published numerous research papers on innovative cellular therapies. His profound understanding of the intricate biological processes underpinning cell-based treatments makes him an ideal addition to Celularity's Board of Directors. Leveraging Dr. Ling?s outside perspective and deep expertise in stem cell therapy, Celularity hopes to unlock the full potential of placental-derived cells and tissues.

Dr. Ling brings more than 30 years of experience in pharmaceutical, governmental, and academic organizations to his new role. Most recently, he co-founded On Demand Pharmaceuticals ? developing advanced, miniaturized, and automated pharmaceutical manufacturing systems that create from precursors to final formulated drugs.

He also serves as a Professor of Neurology and an Attending Neurocritical Care physician at Johns Hopkins University and Hospital and the Uniformed Services University of the Health Science (USUHS). Dr. Ling previously served as the Founding Director of the Biological Technologies Office at the Defense Advanced Research Projects Agency (DARPA) and as Assistant Director for Medical Innovation of the Science Division in President Obama?s White House Office of Science and Technology Policy (OSTP). He is a retired U.S. Army colonel who served for 27 years and was deployed to Iraq and Afghanistan.

Dr. Ling obtained his medical degree from Georgetown University and his doctorate in Pharmacology is from Cornell University. He was a postdoctoral research fellow at Memorial Sloan Kettering Cancer Center, completed his neurology residency at Walter Reed Army Medical Center, and his Neuro Critical Care fellowship at Johns Hopkins. Dr. Ling has published over two hundred peer-reviewed articles, book chapters and reviews.

He is a member of the honor societies of Alpha Omega Alpha, Sigma Xi, and the Military Medical Order of Merit. He is a fellow of the American Neurological Association, American Academy of Neurology and Neurocritical Care Society. Dr. Ling is a member of the Society for Critical Care Medicine, the American Society of Pharmacology and Experimental Therapeutics, and AMSUS (the Association of Military Surgeons of the United States).

Celularity also announced that Andrew von Eschenbach, M.D., will step down from his position on the Board of Directors.